Loading...
Investigators often use composite outcomes as a primary measure of efficacy in clinical trials in cardiovascular disease, because the most important individual outcomes, such as mortality, occur infrequently. However, composite outcomes may obscure differences in the relative importance of the individual components. In this study, researchers used a Japanese registry cooperative to evaluate the effect on mortality of three common, nonfatal adverse cardiovascular events in patient who underwent percutaneous coronary intervention (PCI): hospitalization for heart failure (HFH), acute coronary syndrome (ACS), and major bleeding. There were 10,482 patients: 27% with ST-segment−elevation myocardial infarction (STEMI), 25% with non-STEMI or…